Edition:
United Kingdom

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

18.92USD
20 Jun 2018
Change (% chg)

$0.51 (+2.77%)
Prev Close
$18.41
Open
$18.40
Day's High
$18.97
Day's Low
$18.20
Volume
34,526
Avg. Vol
45,425
52-wk High
$23.67
52-wk Low
$12.65

Latest Key Developments (Source: Significant Developments)

Mersana Presents Interim Dose-Escalation Data On XMT-1522 In Select Cancers At Asco 2018
Monday, 4 Jun 2018 

June 4 (Reuters) - Mersana Therapeutics Inc ::MERSANA PRESENTS INTERIM DOSE-ESCALATION DATA ON XMT-1522 IN SELECT CANCERS AT ASCO 2018.MERSANA THERAPEUTICS-NEW EFFICACY,SAFETY DATA FROM ONGOING PHASE 1 DOSE-ESCALATION&EXPANSION STUDY EVALUATING CO'S INVESTIGATIONAL COMPOUND, XMT-1522.  Full Article

Mersana Therapeutics Reports Q1 Loss Per Share $0.54
Monday, 14 May 2018 

May 14 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q1 LOSS PER SHARE $0.54.Q1 EARNINGS PER SHARE VIEW $-0.61 -- THOMSON REUTERS I/B/E/S.COLLABORATION REVENUE FOR Q1 2018 WAS APPROXIMATELY $3.1 MILLION, COMPARED TO $4.3 MILLION.Q1 REVENUE VIEW $3.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Mersana Therapeutics Q4 Loss Per Share $0.61
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q4 LOSS PER SHARE $0.61.Q4 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.ENROLLMENT ON TRACK FOR PHASE 1 TRIAL OF XMT-1522 PATIENTS WITH ADVANCED TUMORS EXPRESSING HER2.COLLABORATION REVENUE FOR Q4 2017 WAS ABOUT $3.3 MILLION VERSUS $12.0 MILLION FOR SAME PERIOD IN 2016.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2017 WERE $125.2 MILLION.MERSANA THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL ENABLE CO TO FUND OPERATING PLAN THROUGH AT LEAST MID-2019.  Full Article

Mersana announces third quarter loss of $0.35 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Mersana Therapeutics Inc :Mersana announces third quarter 2017 financial results and provides business updates.Qtrly ‍loss per share $0.35​.Cash, cash equivalents and marketable securities as of Sept 30, 2017 were $133.4 million, compared with $100.3 million as of Dec 31, 2016​.Expects that cash, cash equivalents and marketable securities will enable it to fund operating plan through at least mid-2019​.  Full Article

Mersana announces FDA clearance of IND application for XMT-1536
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Mersana Therapeutics Inc :Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b.‍U.S. FDA cleared company's investigational new drug application to begin phase 1 clinical trials for XMT-1536​.  Full Article

Mersana Therapeutics says Pfizer reports 9.8 percent passive stake in Mersana as of July 3 - SEC Filing
Thursday, 13 Jul 2017 

July 13 (Reuters) - Mersana Therapeutics Inc :Pfizer Inc. reports 9.8 percent passive stake in Mersana Therapeutics Inc as of July 3 - sec filing.  Full Article

Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017
Friday, 7 Jul 2017 

July 7 (Reuters) - Rock Springs Capital Management LP: :Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing.  Full Article

Mersana Therapeutics announces pricing of initial public offering
Wednesday, 28 Jun 2017 

June 27 (Reuters) - Mersana Therapeutics Inc ::Mersana Therapeutics announces pricing of initial public offering.Says initial public offering of 5.00 million common shares priced at $15.00 per share.  Full Article

BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61

* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES